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The aims of the present study were to investigate, in diabetes mellitus (DM), the mechanism of NOX4 up-regulation, its link with 5′ adenosine
monophosphate-activated protein kinase (AMPK) inactivation and transforming growth factor (TGF) ß-1 signaling in determining the accumulation of kidney
extracellular matrix (ECM), and the possible action of cocoa enriched with polyphenols (CH) in these events. After 16 weeks of DM, spontaneously hypertensive
rats showed increased kidney TGFβ-1 levels and expression of phosphorylated smad2, collagen IV and fibronectin in parallel with elevated NOX4 expression and
reduced phosphorylated AMPK. CH treatment in diabetic rats prevented all of these abnormalities. In immortalized human mesangial cells exposed to high
glucose (HG), or TGFβ-1, CH, nicotinamide adenine dinucleotide phosphate blocker, or silencing NOX4 ameliorated enhanced phosphorylated smad2 and
collagen IV. Reduction in phosphorylated AMPK induced by HG or TGFβ-1 was ameliorated by CH or activation of AMPK, which reduced phosphorylation of
smad2 and collagen IV via reduction in NOX4 expression. The effects of CH were abolished by AMPK blockade. These results suggest that inactivation in AMPK
leads to NOX4 up-regulation, activation of TGFβ-1 signaling and increased ECM accumulation. Additionally, increased TGF-ß1 per se leads to the amplification of
ECM production by reducing AMPK and promoting the activation of NOX4. It is suggested that the activation of AMPK by CH followed by reduction in NOX4/
TGFβ-1 signaling may have a therapeutic potential in diabetic nephropathy.
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Diabetic nephropathy (DN) is the leading cause of chronic renal
failure, and it is considered a primary indication for dialysis and
transplantation inmost parts of the world [1]. This scenario is unlikely
to change — in fact, it may even get worse — because the number of
patients with diabetes mellitus (DM) is expected to increase,
especially in developing countries [2]. Therefore, it is essential to
identify new therapeutic targets and drugs to treat DN, which is a
serious complication. Several lines of evidence suggest that in DM,
excess amounts of reactive oxygen species (ROS) are involved in the
pathogenesis of DN by promoting the accumulation of extracellular
matrix (ECM) [1,3,4]. ECM accumulation contributes to the thickening
of glomerular and tubular basement membranes, leading to glomer-
ulosclerosis and tubulointerstitial fibrosis [5,6]. In diabetes, it has
been demonstrated that transforming growth factor (TGF) β-1 is a
crucial cytokine involved in renal ECM accumulation [7]. TGFβ-1
contributes to glomerular ECM accumulation by increasing the
expression of ECM genes such as collagens I and IV and fibronectin
and by decreasing ECM degradation through the elevated expression
of plasminogen activator inhibitor-1 [8–10]. Inhibiting TGFβ-1
attenuates the high glucose (HG)-induced changes in gene expression
that lead to the accumulation of ECM both in vitro and in animal
models of DN [11,12].
Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-
derived ROS have been shown to play a significant role in injury to
various organs, including the kidney [13]. NOX4, one of the main
subunits of NADPH oxidase, is abundantly expressed in rat andmouse
glomeruli as well as in mesangial, podocyte and tubular cells [14,15].
The up-regulation of NOX4 has been linked with a rise in fibronectin
[16–18] and TGFβ-1 [17] in mesangial and tubular cells exposed to
HG. NOX4 has also been shown to mediate an increase in mesangial
hypertrophy under angiotensin II treatment [19,20] as well as
fibronectin rise [21]. However, the role of NOX4 in ECM accumulation
via TGFβ-1 signaling in the kidney under diabetic conditions is
unclear. NOX4 is also implicated in TGFβ-1-induced ECM accumula-
tion in fibroblasts, contributing to their differentiation into a
profibrotic myofibroblast phenotype [22]. Very early responses of
mesangial cells to HG include autocrine TGFβ-1 stimulation of protein
kinase C isozymes and consequent generation of ROS by NADPH
oxidase [23]. Similarly, tubular cells exposed to TGFβ-1 showed
enhanced NOX4 expression [24]. However, evidence about the role of
NOX4 in TGFβ-1 induction in the amplification of ECM accumulation
in mesangial cells is lacking.
5′ Adenosine monophosphate-activated protein kinase (AMPK), a
serine/threonine kinase, is an energy sensor whose activity is
regulated by glucose [25]. AMPK is a heterotrimeric protein consisting
of a catalyticα-subunit and regulatory β- and γ-subunits. The activity
and subunit composition of AMPK are expressed in a cell- and tissue-
specific manner, with the α1- and α2-subunits expressed in the
kidney and in glomerular cells [26]. The activation of AMPK requires
the phosphorylation of a critical threonine residue (Thr172) in the
activation loop of the α-subunit [27]. Diabetes [28–30], as well as the
exposure of mesangial [29–31], tubular [24] and podocyte [32] cells to
HG, has been shown to inhibit phosphorylation in the Thr172 residue
of AMPK. The inactivation of AMPK has been associated with
profibrotic damage, because 5-aminoimidazole-4-carboxamide ribo-
nucleotide (AICAR), an inducer of AMPK, ameliorated hypertrophy in
the kidney cortex of diabetic rats [28] and prevented epithelial–
mesenchymal transition in tubular cells exposed to HG or TGFβ-1
[24]. Recently, the activation of AMPK has been linkedwith the down-
regulation of NOX4 expression and subsequent reduction in ROS
formation in mesangial [33] and podocyte [32] cells under HG.
However, whether AMPK inactivation is linked with ECM accumula-
tion via TGFβ-1 signaling and TGFβ-1 per se contributes to furtherreduction in AMPK with consequent activation of NOX4 and
amplification on ECM deposition in DM is unknown.
Clinical and experimental studies have demonstrated that cocoa
has the potential to be beneficial in different conditions [34]. Cocoa
contains a number of polyphenolic compounds that have been shown
to inhibit ROS formation and enhance the antioxidant capacity in
vascular endothelial cells [34], and it also reduces the risk of
cardiometabolic disorders in conditions such as type 2 diabetes,
hypertension and metabolic syndrome [35]. A variety of acute or
chronic clinical studies have also shown the beneficial effects of a
high-polyphenol cocoa diet in diabetic patients [36] as well as in
prehypertensive or stage 1 hypertensive subjects [37] via reduction in
oxidative stress and hence an improvement of endothelial function.
However, the potential of cocoa for nephroprotection in a diabetic
kidney has not yet been investigated.
The aims of the present study were to assess, under diabetic
conditions, the contribution and mechanism of NOX4 activation
leading to ECM accumulation mediated by TGFβ-1 signaling and the
role of AMPK down-regulation in this process, and finally to
investigate the effects of cocoa enriched with polyphenols (CH) in
these events.
2. Materials and methods
2.1. Reagents
All reagents were purchased from Sigma (St. Louis, MO, USA), unless otherwise stated.
2.2. Identification and quantification of polyphenols in cocoa extract
The identification of components in cocoa enriched in polyphenols was assessed by
high-performance liquid chromatography (Waters, Milford, MA, USA) [38].
2.3. Animals and study design
This study protocol was approved by the local committee for ethics in animal
research (CEEA/IB/UNICAMP, protocol no. 1834-1). Spontaneously hypertensive
rats (SHRs) supplied by Taconic (Germantown, NY, USA) were used in this study.
We chose to induce diabetes in SHR rats because they present a more progressive
form of renal disease [39], because we have vast experience with this model [3,40–42],
and because of the frequent association of diabetes with hypertension in human
diabetic kidney disease. Diabeteswas induced in 12-week-old hypertensivemale SHR
rats via a single intravenous injection of streptozotocin (STZ; 60 mg/kg in sodium
citrate buffer, pH 4.5). The control SHR rats received only a vehicle (citrate buffer).
Rats with plasma glucose concentrations of N15 mmol/L were considered diabetic.
The systolic blood pressure was obtained with tail-cuff plethysmography using a 229
blood pressure amplifier/pump (Victory Boulevard, CA, USA). Forty-eight hours after
STZ injection, the diabetic rats were randomly assigned to receive no treatment or
treatment with CH (Acticoa; Barry Callebaut, Louviers, France; 24 mg/kg per day)
administered by gavage. This dose of cocoa was based on a previously published
article [43].
During the study, the diabetic rats subcutaneously received 2 units of insulin
(human insulin HI-0310; Lilly, Indianapolis, IN, USA) three times per week. After 16
weeks of diabetes induction, the rats were killed, their kidneys were removed, and a
piece of the cortex was used for protein isolation. The remaining kidney cortex was
snap-frozen at−80°C for future assays. For the experiments assessing the role of cocoa
in diabetic rats, at least three rats were used for each experiment.
2.4. Albumin excretion rate
The albumin excretion rate was determined in 24-h urine collection with an
enzyme-linked immunosorbent assay (ELISA) kit (Nephrat II; Exocell, Philadelphia, PA,
USA) [42].
2.5. Renal histopathology
Four-micrometer kidney sections were stained with periodic acid-Schiff (PAS) and
matrix mesangial expansion and quantified by Leica Application Suite (LAS Image
Analysis), as derived from an assessment of 30 glomeruli from each rat.
2.6. Immortalized human mesangial cell culture
Immortalized human mesangial cells (iHMCs) were kindly provided by Dr. Nestor
Schor (Department of Medicine, Nephrology Division, Federal University of São Paulo,
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Maximilian University of Munich, Germany) [44]. The concentrations of treatments
used in the HG (30 mM) medium or TGFβ-1 (5 ng/ml) in all experiments were chosen
after carrying out a thiazolyl blue tetrazolium bromide assay (data not shown).
2.7. Experimental conditions of iHMCs
iHMCs were kept without serum for 24 h in NG (5.5 mM), HG or TGFβ-1 alone or
with different treatments. iHMCs were also treated with 41 nM of epicatechin, which
corresponds to its 12% composition within 100 ng/ml of CH.
2.8. Transient transfection with small interfering RNAs
The small interfering RNA (siRNA) duplexes and scrambled siRNA corresponding
to human NOX4 were obtained from Invitrogen (Carlsbad, CA, USA). The transient
transfection of siRNAs was carried out using lipofectamine transfection reagent
(Invitrogen). siRNA and scrambled (200 nM) for human NOX4 were formulated with
lipofectamine transfection reagent according to the manufacturer's instruction after
incubation for 24 h in the absence of serum and antibiotics.
2.9. Quantification of TGFβ-1 levels
TGFβ-1 was quantified via commercially available ELISA TGFβ-1 kit (R&D Systems
Inc., MN, USA) according to the manufacturer's instructions [45].
2.10. NADPH oxidase activity
NADPH oxidase activity was measured by the lucigenin-enhanced chemilumines-
cence method [42].
2.11. Western blot analysis
The samples and Western blots were prepared as described previously [40–42].
The following primary antibodies were used: goat anti-type IV collagen (1:500;
Southern Biotech, Birmingham, AL, USA), rabbit anti-NOX4 (1:500; Santa Cruz
Biotechnology, Danvers, MA, USA), mouse anti-nitrotyrosine (1:2.000; Upstate, Cell
Signalling, Danvers, MA, USA), goat anti-fibronectin (1:500; Calbiochem, La Jolla, CA,
USA), rabbit and mouse phosphorylated smad2 and smad3 (1:500; Cell Signalling
Technology), rabbit phosphorylated Thr172 AMPK (1:500, Cell Signalling Technology),
total rabbit smad2, smad3 and AMPK (1:1000; Cell Signalling Technology). To verify
the uniformity of protein load and transfer efficiency across the test samples,
membranes were reprobed with actin (goat polyclonal anti-actin antibody, diluted
1:1000; Santa Cruz Biotechnology).
2.12. Immunohistochemistry
The following primary antibodies were used: goat anti-type IV collagen (Southern
Biotech), 1:200 for mouse anti-nitrotyrosine (Upstate, Cell Signaling) and with 1:50
dilution for mouse monoclonal anti-8-OHdG antibody (N45.1; Japan Institute for the
Control of Aging, Japan). Collagen IV and nuclear 8-OHdG intensity in both the
glomerulus and the tubulointerstitial area were quantified by Leica Application Suite
(LAS Image Analysis) in 50 sequential high-power microscopic fields (×400).
2.13. 2′,7′-Dichlorodihydrofluorescein diacetate measurement of ROS production
Intracellular ROS levels were measured by 2′,7′-dichlorodihydrofluorescein
diacetate as previously described [40].
2.14. Statistical analysis
Results are expressed as mean±standard error of mean (S.E.M.), except for
albuminuria, which is expressed as geometric mean and confidence of interval, and
they were analyzed by the Kruskal–Wallis test (for multiple groups) and Mann–
Whitney U test (for two groups). Comparisons between multiple groups are performed
by one-way analysis of variance followed by the Bonferroni test, whereas those
between two groups are performed by a t-test. Analyses are considered significant at
Pb.05. The analyses were performed using StatView software (SAS Institute Inc.,
Cary, NC, USA).3. Results
3.1. CH attenuated diabetes-induced ECM accumulation and
inactivation of AMPK in SHR diabetic rats
Supplementary Table 1 depicts the composition of CH used in
our experiments. CH treatment in diabetic SHR rats had no effecton body weight, systolic blood pressure, glycemic control, food
intake and albuminuria (Supplementary Table 2 and Supplemen-
tary Figure S1a). However, CH reversed the increase in the
glomerular mesangial matrix expansion of diabetic SHR rats
(Fig. 1A and B) and reduced the expression of collagen type IV
(Fig. 1C and D and Supplementary Figures S1b–c) and fibronectin
(Fig. 1E and F). CH treatment also ameliorated the diabetes-
induced rise of phosphorylated smad2 expression (Fig. 1G and H)
in parallel with an inhibition in TGFβ-1 levels in the kidney cortex
of SHR diabetic rats (Supplementary Figure S1d). CH also
ameliorated the diabetes-induced reduction of phosphorylated
AMPK in the kidney of SHR diabetic rats (Fig. 1I and J), suggesting
that under diabetes, CH may block TGFβ-1-induced ECM accumu-
lation via the activation of AMPK.3.2. CH attenuated diabetes-induced oxidative stress in SHR diabetic rats
CH reduced the diabetes-induced rise in oxidative stress by
suppressing ROS formation via NADPH oxidase (Fig. 2A) as well as the
expression of NOX4, an NADPH oxidase subunit (Fig. 2B and C).
Furthermore, CH ameliorated the superoxide-induced nitrosative
stress and DNA damage in diabetic SHR rats, as shown by Western
blot for nitrotyrosine (Fig. 2D and E) and immunohistochemistry for
8-OHdG DNA respectively (Fig. 2F and G). To further clarify the
sequence of events in the diabetes-induced inactivation of AMPK and
induction in NADPH oxidase activity resulting in ECM accumulation
mediated by TGFβ-1 signaling as well as the mechanism of action of
CH in alleviating renal profibrotic damage, we used an in vitro model
of iHMCs.3.3. CH reduced oxidative stress via inhibition in NADPH oxidase activity
in iHMCs exposed to HG
Qualitative (Fig. 3A) and quantitative (Fig. 3B) assessment showed
a significant rise in ROS formation in iHMCs exposed to HG that was
prevented with CH treatment. We next tested which pathway was
involved in ROS generation and was blocked by CH in iHMCs under
HG. Toward this end, we estimated the effects of CH on the production
of ROS in the presence of an NADPH oxidase blocker (DPI), a nitric
oxide synthase enzyme blocker (L-NAME) to assess eNOS uncoupling,
and an inhibitor of mitochondria electron transport complex I
(rotenone). Fluorometric analysis (Fig. 3B) showed that in the
presence of DPI, CH could not further reduce ROS production.
However, in the presence of rotenone or L-NAME, CH could further
reduce ROS production. These results suggest that the inhibition of
NADPH oxidase is the primary mechanism via which CH confers
protection against HG-induced ROS formation in iHMCs. Accordingly,
ROS formation via NADPH oxidase was significantly higher in iHMCs
treatedwith HG andwas prevented by CH treatment (Fig. 3C). CHwas
also found to significantly reduce the HG-induced rise in the
expression of NOX4 (Fig. 3D and E).
3.4. CH prevented TGFβ-1-induced ECM accumulation by decreasing
NOX4 expression in iHMCs exposed to HG
The expression levels of both collagen IV and phosphorylated
smad2 were significantly elevated in iHMCs exposed to HG
(Supplementary Figures S2a–d) and were reduced to the same
extent with CH alone or associated with DPI (Supplementary Figures
S2a–d). In parallel, CH or DPI individually or together abrogated to
the same extent HG (Supplementary Figure S2e) in TGFβ-1 release in
the supernatants of iHMCs. Knocking down NOX4 in iHMCs at NG
reduced its expression levels to ~77%, confirming the efficiency of
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Fig. 1. CH treatment in diabetic SHR rats prevents ECM accumulation. Photomicrographs (A) and quantification (B) of the glomerular PAS-stained areas from control (SHR CT; n=6),
diabetic (SHR DM; n=6), and diabetic treated with CH (SHR DM CH; n=6) rats. Original magnification ×400 counterstained with hematoxylin. Scale bar=50 μm. Bars represent mean
±S.E.M. of three independent experiments. *P=.014 vs. SHR CT. Representative Western blot analysis for collagen IV (C), fibronectin (E), phosphorylated smad2 (psmad2) (G) and
phosphorylated AMPK (Thr172) (pAMPK) (I) in the renal cortex of SHR CT (n=6), SHR DM (n=6) and SHR DM CH (n=6) rats followed by densitometric analysis and quantification of
collagen IV/β-actin ratio (D), fibronectin/β-actin ratio (F), psmad2/Tsmad2/β-actin ratio (H) and pAMPK/TAMPK/β-actin ratio (J). Bars represent mean±S.E.M. of band intensities
(arbitrary densitometric units) of three independent experiments. *Pb.0001 vs. SHR CT.
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the same extent HG-induced NOX4 expression (Fig. 4A and B) as
well as phosphorylation of smad2 (Fig. 4C and D) and collagen IV
(Fig. 4E and F), suggesting that CH may inhibit HG-induced ECM
accumulation through inhibition in the NOX4-induced activation of
the TGFβ-1 pathway.3.5. CH abrogated ECM accumulation via NOX4/TGFβ-1 signaling by
activation of AMPK under HG in iHMCs
The expression levels of phosphorylated AMPK were significant-
ly reduced in iHMCs (Fig. 5A and B) exposed to HG, and this was
reversed by CH treatment. The activation of AMPK with AICAR or
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Fig. 2. CH treatment in diabetic SHR rats prevents oxidative stress (A). NADPH-dependent ROS generation in renal cortical homogenate from control (SHR CT; n=6), diabetic
(SHR DM; n=6) and diabetic treated with CH (SHR DM CH; n=6) rats expressed as relative luminescence units (RLU)/mg protein. Bars represent mean±S.E.M. of
three independent experiments. *P=.012 vs. SHR CT (B). Representative Western blot analysis for NOX4 in the renal cortex of SHR CT (n=6), SHR DM (n=6) and SHR DM
CH (n=6) rats followed by densitometric analysis and quantification of NOX4/β-actin ratio (C). Bars represent mean±S.E.M. of band intensities (arbitrary densitometric
units) of three independent experiments. *P=.02 vs. SHR CT (D). Representative Western blot analysis for nitrotyrosine in the renal cortex of SHR CT (n=6), SHR DM (n=6)
and SHR DM CH (n=6) rats followed by densitometric analysis and quantification of nitrotyrosine/β-actin ratio (E). Bars represent mean±S.E.M. of band intensities
(arbitrary densitometric units) of three independent experiments. *P=.03 vs. SHR CT. Photomicrographs (F) and quantification (G) of the immunohistochemistry of oxidative
stress-induced DNA damage (8-OHdG) in the kidney cortex. Glomerular and tubulointerstitial cells containing 8-OHdG were identified by their brown color (darker) for SHR
CT (n=6), SHR DM (n=6) and SHR DM CH (n=6) rats. Original magnification ×400 counterstained with hematoxylin. Scale bar=50 μm. The bars represent mean±S.E.M. of
three independent experiments. *P=.011 vs. SHR CT.
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Fig. 3. CH reduces ROS production via NADPH oxidase in iHMCs under HG. iHMCs were
kept for 24 h in NG (5.5 mM, n=4) or HG (30 mM, n=4) and treated as indicated (A).
Qualitative assessment of total ROS. Total ROS levels were assessed by incubating
iHMCs with 10 μM DCF-DA for 30 min. Images were then taken under fluorescent
microscope (B). iHMCs in HGwere treatedwith CH (100 ng/ml, n=6), DPI (50 nM, n=6),
L-NAME (100 μM, n=6), rotenone (10 μM, n=6), or DPI, L-NAME, and rotenone in
combination with CH (n=6). Mannitol (30 mM, n=6) was used as an osmotic control.
Total ROS levels were quantified as explained in panel A via fluorometric measurement.
The bars represent mean±S.E.M. of three independent experiments, and values are
expressed as percentage of fluorescence units. *Pb.0001 vs. NG and §P=.005 vs. NG (C).
NADPH-dependent ROS generation in iHMC in conditions as indicated and expressed as
relative luminescence units (RLU)/μg protein. The bars represent mean±S.D. of three
independent experiments. *P=.001 vs. NG (D). Representative Western blot analysis of
NOX4 in lysate of iHMCs followed by densitometric analysis and quantification (E) of
NOX4/β-actin ratio. The bars represent mean±S.E.M. of band intensities (arbitrary
densitometric units) of three independent experiments. *Pb.0001 vs. NG.
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AMPK (Fig. 5A and B), increase in NOX4 (Fig. 5C and D),
phosphorylation of smad2 (Fig. 5E and F) and collagen IV (Fig. 5G
and H) expressions. These effects of CH were inhibited by
compound C, an AMPK blocker (Supplementary Figures S3a–h).
The activation of AMPK at NG led to a significant reduction in the
expression levels of NOX4, phosphorylated smad2 and collagen IV
(Fig. 5C–H), whereas the blockade of AMPK produced opposite
effects (Supplementary Figures S3c–h). These observations clearly
demonstrated the relationship between AMPK, NOX4, smad2 and
collagen IV, where HG decreases AMPK phosphorylation, promoting
the activation of NOX4, smad2 phosphorylation, and ultimately
increasing the expression of collagen IV.3.6. CH inhibited oxidative stress via inhibition in NADPH oxidase
activity in iHMCs exposed to TGFβ-1
To assess if the increase in TGFß-1 induced by HG will further
amplify the effects of HG on ROS production and, ultimately, the
increase in ECM accumulation, we assess the effects of exposition of
iHMCs to TGFß-1. The quantitative (Supplementary Figure S4a)
assessment of ROS production showed a significant rise in ROS
formation in iHMCs exposed to TGFβ-1, whichwas preventedwith CH
treatment. The treatment of iHMCs exposed to TGFß-1 with different
blockers suggested that the inhibition of NADPH oxidase is the
primary mechanism via which CH confers protection against TGFβ-1-
induced ROS formation. Accordingly, ROS formation via NADPH
oxidase was significantly higher in iHMCs treated with TGFβ-1 and
was prevented by CH treatment (Supplementary Figure S4b). CH was
also found to significantly reduce the TGFβ-1-induced rise in the
expression of NOX4 (Supplementary Figures S4c–d).3.7. AMPK activation by CH inhibited amplification in ECM accumulation
induced by TGFβ-1/NOX4 signaling in iHMCs exposed to TGFβ-1
The expression levels of both collagen IV and phosphorylated
smad2 were significantly elevated in iHMCs exposed to TGFβ-1
(Fig. 6A–D), and they were reduced to the same extent with CH alone
or associated with DPI (Fig. 6A–D). NOX4 silencing or CH reduced to
the same extent TGFβ-1-induced NOX4 expression (Supplementary
Figures S5a–b) as well as phosphorylation of smad2 (Fig. 6E and F)
and collagen IV (Supplementary Figures S5c–d), suggesting that CH
may further inhibit TGFβ-1-induced amplification in ECM deposition
through abrogation in NOX4 expression.
The expression levels of phosphorylated AMPK were signifi-
cantly reduced in iHMCs exposed to TGFβ-1, and this was
reversed by CH treatment (Fig. 7A and B). The activation of
AMPK with AICAR or CH treatment blocked to the same extent
TGFβ-1-induced reduction in phosphorylated AMPK (Fig. 7A and
B). In addition, the cotreatment of AICAR with CH reduced to the
same extent the increase in NOX4 (Fig. 7C and D), phosphory-
lation of smad2 (Fig. 7E and F) and collagen IV (Fig. 7G and H)
expressions under TGFβ-1. These effects were blocked by the
inhibition of AMPK with compound C (Supplementary Figures
S6a–h). Blockade of TGFβ-1 receptor I alone or together with CH
ameliorated to the same extent HG-induced reduction in
phosphorylated AMPK (Supplementary Figures S7a-b), induction
in NOX4 expression (Supplementary Figures S7c–d) and subse-
quent activation of phosphorylated smad2 (Supplementary Fig-
ures S7e–f) and collagen IV (Supplementary Figures S7g–h)
expression. This clearly demonstrates that under HG, TGFβ-1
can amplify ECM accumulation via its receptor I and subsequent
inactivation of AMPK.
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Fig. 4. CH reduces HG-induced ECM accumulation via inhibition in NOX4 expression under HG in iHMCs. Representative Western blot analysis of NOX4 (A), phosphorylated smad2
(psmad2) (C) and collagen IV expression (E) in iHMCs under NG (n=4) alone or in combination with transfection of scramble NOX4 plasmid (src 200 nM, n=4) or with transfection of
siRNA NOX4 plasmid (200 nM, n=4) or HG (n=4) alone or in combination with designated treatments followed by densitometric analysis and quantification of NOX4/β-actin ratio
(B), psmad2/Tsmad2/β-actin ratio (D) and collagen IV/β-actin ratio (F). The bars represent mean±S.E.M. of band intensities (arbitrary densitometric units) of three independent
experiments. *Pb.0001 vs. NG.
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reduces ECM accumulation via activation of AMPK in iHMCs exposed to
HG or TGFβ-1
Since epicatechin is an important constituent of CH (Supplemen-
tary Table 1), corresponding to 12% of total catechins, we assessed the
effects of this polyphenol in iHMCs exposed to HG. The quantitative
(Supplementary Figure S8a) assessment of ROS production showed
that epicatechin treatment reduces ROS formation in iHMCs exposed
to HG. This effect was obtained mainly by the blockade of NADPH
oxidase (Supplementary Figures S8a–b). Epicatechin was also found
to significantly reduce the HG-induced rise in the expression of NOX4
(Supplementary Figures S8c–d) as well as HG-induced TGFβ-1 release
(Supplementary Figure S8e) in the iHMC supernatants. Similarly to
CH, epicatechin treatment abrogated the reduction in phosphorylated
AMPK (Supplementary Figures S9a–b), increase in NOX4 (Supple-
mentary Figures S9c–d), phosphorylated smad2 (Supplementary
Figures S10a–b) and collagen IV (Supplementary Figures S10c–d)
expressions in iHMCs exposed to HG and TGFβ-1. These effects wereblocked by the inhibition of AMPK with compound C (Supplementary
Figures S9a–d and S10a–d).
4. Discussion
Here, we show that in the kidney, under diabetic conditions, NOX4
is up-regulated as a consequence of the inactivation of AMPK, leading
to the activation of TGFβ-1 signaling via TGFβ-1 receptor I with
subsequent phosphorylation in smad2 and increase in collagen IV.We
also show, for the first time, that TGFβ-1 can amplify ECM
accumulation in mesangial cells due to the inactivation of AMPK,
leading to a further activation of NOX4. CH or epicatechin can
interrupt this sequence of events and abrogate ECM accumulation
under both HG and TGFβ-1. So far, the role of NOX4 in ECM
accumulation via TGFβ-1 signaling has not been assessed in great
detail [13]. In mesangial cells, NOX4 has been shown to mediate HG-
induced fibronectin expression [16] as well as hypertrophy under
angiotensin exposure [19–21]. Our results identify, for the first
time, NOX4 as an upstream critical activator in mediating ECM
AC
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Fig. 5. CH inhibits HG-induced NOX4 expression and subsequent TGFβ-1 activation of ECM accumulation via the activation of AMPK in iHMCs. Representative Western blot analysis for
phosphorylated AMPK (pAMPK) (Thr172) (A), NOX4 (C), phosphorylated smad2 (psmad2) (E) and collagen IV expression (G) in iHMCs under NG (n=4) alone or in combination with
an AMPK activator (AICAR 1 mM, n=4) or HG (n=4) alone or in combination with designated treatments followed by densitometric analysis and quantification of pAMPK/TAMPK/β-
actin ratio (B), NOX4/β-actin ratio (D), psmad2/Tsmad2/β-actin ratio (F) and collagen IV/β-actin ratio (H). The bars represent mean±S.E.M. of band intensities (arbitrary
densitometric units) of three independent experiments. *Pb.0001 vs. NG.
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exposed to HG. Silencing NOX4 abrogated HG-induced smad2
phosphorylation and collagen IV expression. Importantly, ROS
production has also been shown to increase after TGFβ-1
exposure in mesangial cells via increase in the p22phox subunit
of NADPH oxidase [23]. However, the role of NADPH oxidase and,
specifically, NOX4 in amplifying ECM accumulation via TGFβ-1
signaling has not yet been established. Furthermore, our results
demonstrated, for the first time, that NOX4 in mesangial cells
mediates an amplification cascade via TGFβ-1 leading to an
additional increment of ECM deposition. This is supported by our
findings that silencing NOX4 abrogated TGFβ-1-induced smad2
phosphorylation and, in turn, collagen IV expression. In parallel,
the blockade of TGFβ-1 receptor I under HG abrogated the
increase in NOX4 expression and subsequent smad2 phosphory-
lation. Previous studies on kidney fibroblasts have shown that
TGFβ-1 via NOX4 is responsible for differentiation of these cellsto myofibroblasts [22,46]. In this last study, high NOX4 levels
were a consequence of activation in smad3 phosphorylation via
TGFβ-1-induced receptor I activation. Our results attribute smad2
phosphorylation to activation in NOX4 expression under TGFβ-1,
possibly due to differences in the type of kidney cells used as
well as culture conditions. Nevertheless, our data are in
agreement with a study on tubular cells [47], showing that
TGFβ-1 mediates epithelial mesenchymal transition (EMT) via
ROS-induced smad2 phosphorylation, though neither the involve-
ment of NADPH oxidase nor NOX4 was assessed in that study.
The inactivation of AMPK has been known to contribute to
ECM accumulation and kidney hypertrophy in DN [28–30]. Recent
studies on mesangial cells and podocytes have shown that the
inactivation of AMPK accounts for NOX4-induced ROS formation
under HG [32,33]. However, the link between inactivation in
AMPK and ECM accumulation via TGFβ-1 signaling was not
assessed. Our results suggest that the inactivation of AMPK
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Fig. 6. CH reduces TGFβ-1-induced amplification of ECM accumulation via inhibition of NOX4 expression in iHMCs. Representative Western blot analysis of phosphorylated smad2
(psmad2) (A and E) and collagen IV expression (C) in iHMCs under NG (n=4) alone or in combination with transfection of scramble NOX4 plasmid (src 200 nM, n=4) or with
transfection of siRNA NOX4 plasmid (200 nM, n=4) or TGFβ-1 (5 ng/ml, n=4) alone or in combination with designated treatments followed by densitometric analysis and
quantification of psmad2/Tsmad2/β-actin ratio (B and F) and collagen IV/β-actin ratio (D). The bars represent mean±S.E.M. of band intensities (arbitrary densitometric units) of three
independent experiments. *Pb.0001 vs. NG.
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amplification of ECM accumulation, and they are in agreement with
another study demonstrating the importance of the activation of AMPK
under both HG and TGFβ-1 in abrogating EMT in tubular cells [24].
Maneuvers via the use of plant-derived polyphenols such as
resveratrol have been shown to ameliorate renal injuries in
experimental diabetes via the activation of AMPK [26]. In particular,
resveratrol has been associated with the alleviation of hypertrophy in
both mesangial cells and diabetic rat kidneys after stimulating AMPK
[30]. We have previously demonstrated that green tea improved
markers of renal disease in experimental DM by reducing NOX4
signaling [42]. Here, we show, for the first time, that CH can activate
AMPK, leading to blockade in NOX4 expression and hence abrogation
of ECM accumulation via TGFβ-1 signaling. The ability of cocoa to
activate AMPK shows it to be an important antifibrotic agent because
it could also abrogate TGFβ-1 amplification in ECM accumulation via
blockade in NOX4 expression.Our study has some limitations. CH treatment in diabetic rats
was initiated soon after the induction of diabetes and not after the
development of renal disease. This situation is very unlikely to
occur clinically.
CH treatment did not ameliorate diabetes-induced albuminuria,
and this finding is consistent with previous reports on targeting
TGFβ-1 or its signaling molecules in experimental diabetes using
various approaches, including studies with TGFβ-1 neutralizing
antibodies [11] or smad3 knockout mice [48].
In summary, this study has identified a novel regulatory
mechanism for ECM accumulation under diabetic conditions that
includes AMPK inactivation with subsequent induction in ROS
production via enhancement in NOX4 expression (Fig. 8). High
NOX4 expression increases TGFβ-1 signaling via its receptor I,
phosphorylation in smad2 and collagen IV accumulation. In parallel,
enhanced TGFβ-1 levels amplify profibrotic damage via the further
inactivation of AMPK and reinitiation of the NOX4/TGFβ-1 cycle. CH
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Fig. 7. CH inhibits TGFβ-1-induced amplification of ECM accumulation via inhibition of NOX4 after activation of AMPK in iHMCs. Representative Western blot analysis for
phosphorylated AMPK (pAMPK) (Thr172) (A), NOX4 (C), phosphorylated smad2 (psmad2) (E) and collagen IV expression (G) in iHMCs under NG (n=n=4) alone or in combination
with AICAR (1 mM, n=4) or TGFβ-1 (5 ng/ml, n=4) alone or in combination with designated treatments followed by densitometric analysis and quantification of pAMPK/TAMPK/β-
actin ratio (B), NOX4/β-actin ratio (D), psmad2/Tsmad2/β-actin ratio (F) and collagen IV/β-actin ratio (H). The bars represent mean±S.E.M. of band intensities (arbitrary
densitometric units) of three independent experiments. *Pb.0001 vs. NG.
782 A. Papadimitriou et al. / Journal of Nutritional Biochemistry 25 (2014) 773–784and epicatechin can interrupt this sequence of events and protect the
diabetic kidney.
Supplementary data to this article can be found online at http://dx.
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